Processa Pharmaceuticals, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Processa Pharmaceuticals reported increased net losses in Q3 2025, continued reliance on capital raises, and is pursuing a new cryptocurrency treasury strategy while advancing its oncology pipeline.
NASDAQ
Processa Pharmaceuticals, Inc. reported an increased net loss for Q2 2025 but significantly strengthened its cash position through recent public offerings, extending its capital runway into Q1 2026 while facing ongoing going concern doubts and Nasdaq listing challenges.
NASDAQ
Processa Pharmaceuticals' Q1 2025 results show a net loss of $2.83 million, with ongoing progress in clinical trials for NGC-Cap and a recent public offering providing $4.4 million in net proceeds.
NASDAQ
10-Q: Processa Pharmaceuticals Reports Third Quarter 2024 Results, Initiates Phase 2 Trial for NGC-Cap
Processa Pharmaceuticals reported a net loss of $3.38 million for the third quarter of 2024 and initiated a Phase 2 trial for its lead drug candidate, NGC-Cap.
NASDAQ
Processa Pharmaceuticals reported a net loss of $3.01 million for the second quarter of 2024, while progressing its oncology drug pipeline, including initiating a Phase 2 trial for NGC-Cap.
NASDAQ
Processa Pharmaceuticals reported a net loss of $2.7 million for the first quarter of 2024, while making progress on its NGC-Cap program and securing funding for future trials.